AstraZeneca plc (ADR) (AZN) is Upgraded by Argus to Buy

AstraZeneca plc (ADR) (AZN) was Upgraded by Argus to ” Buy”. Earlier the firm had a rating of “Hold ” on the company shares. Argus advised their investors in a research report released on Aug 29, 2016.

Many Wall Street Analysts have commented on AstraZeneca plc (ADR). AstraZeneca plc (ADR) was Initiated by Argus to “Hold” on Jul 12, 2016.

On the company’s financial health, AstraZeneca plc (ADR) reported $0.83 EPS for the quarter, based on the information available during the earnings call on Jul 28, 2016. Analyst had a consensus estimate of $0.83. The company had revenue of $5603.00 million for the quarter, compared to analysts expectations of $5596.35 million. The company’s revenue was down -4.0 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.21 EPS.

AstraZeneca plc (ADR) closed down -0.02 points or -0.06% at $33.83 with 46,32,250 shares getting traded on Tuesday. Post opening the session at $33.98, the shares hit an intraday low of $33.72 and an intraday high of $34.07 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory inflammation and autoimmunity and infection neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia bipolar disorder and depressive disorder and Synagis for RSV (respiratory syncytial virus) a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9) a treatment for hyperkalaemia a condition associated with increased mortality in patients with chronic kidney disease (CKD) diabetes mellitus (DM) and chronic heart failure (CHF).

AstraZeneca plc (ADR)

Leave a Reply

AstraZeneca plc (ADR) - Is it time to Sell?

Top Brokerage Firms are advising their investors on AstraZeneca plc (ADR). Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.